Clinical Microbiology: Open Access

Biotechnology antiproteinase vaccine in the experiment

Joint Event on 25^th Asia Pacific Biotechnology Congress & 3^rd International Conference on Medical and Clinical Microbiology

May 01-02, 2019 Kyoto, Japan

Divocha Valentina A

Lugansk State Medical University, Ukraine

Posters & Accepted Abstracts: Clin Microbiol

Abstract:

Proteolytic activation is widespread among viruses of different taxonomic groups. Thus, the proteolytic activation of influenza viruses and paramyxoviruses is carried by trypsin-like proteinases of a host cell which hydrolyze the peptide bond between arginine and lysine. The study aims to extract trypsin-like proteinase from the lungs of healthy mice and get hyper immune serum to it for the treatment of experimental influenza. We used the lungs of 100 white mice to isolate trypsinlike proteinase; influenza virus A/PR/8/34; white rats were used to produce hyper immune antiproteinase sera to study their protective function in the body of white mice infected with a lethal dose of influenza A virus. From the lungs of healthy mice 6 isoforms of trypsin-like proteinases were isolated and hyper immune antiproteinase rats’ sera were obtained to them. At the treatment by these sera the white mice, previously infected with a lethal dose of influenza A virus, 60% of the animals under experiment survived only by the use of the serum to the third isoform of trypsin-like proteinase. In the control group, where no treatment was performed, the infected with a lethal dose of influenza virus animals had 100% lethality on the 4-5th day after infection. The results obtained show that it is possible to get antiproteinase vaccine for the flu, which will block the flu virus in the intercellular space and disrupt the development of the pathological process.

Biography :

E-mail: divocha09@ukr.net